The Role of BetaII Isotype of Tubulin in Diagnosis and Development of Prostate Cancer
Abstract
We have previously found that the Beta(sub II) isotype of tubulin occurs in the cell nuclei of a large number of prostate cancers. In this project, we have examined prostate cancers from two groups of prostatectomies, one set originating with patients whose cancer recurred and the other from a mixture of patients. We found that Beta(sub II) was expressed in a substantial fraction of prostate tumors in both sets of patients. We also observed that, for the subclass that expressed Beta(sub II), the Beta(sub II) occurred more frequently in the nuclei and much less frequently in the cytoplasm alone in the set of patients whose cancer is likely to recur. We also examined the distribution of two other isotypes of tubulin, Beta(sub I) and Beta(sub III), in prostate and other cancers. We found that Beta(sub I) was common in all cancers, Beta(sub III) was less common in prostate cancer and that nuclear occurrence of these isotypes was very infrequent in any cancer. Our results suggest that nuclear Beta(sub II) is a promising predictive biomarker for recurrence of prostate cancer while Beta(sub I) and Beta( sub III) are not likely to become good biomarkers.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jan 01, 2003
- Accession Number
- ADA415601
Entities
People
- Richard F. Luduena
Organizations
- University of Texas Health Science Center at San Antonio